Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01683045
Other study ID # 400-02
Secondary ID ATTAC-AF
Status Terminated
Phase N/A
First received September 7, 2012
Last updated April 22, 2014
Start date September 2012
Est. completion date May 2014

Study information

Verified date April 2014
Source Endoscopic Technologies, Inc
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate that the Estech COBRA Surgical System is an effective treatment for patients with irregular heart beats who are undergoing heart surgery.


Description:

The objective of the trial is to demonstrate that the creation of epicardial and endocardial lesions with temperature-controlled radiofrequency (TCRF) ablation applied using the Estech COBRA® Surgical System during concomitant heart surgery is a safe and effective treatment for non-paroxysmal atrial fibrillation (AF).


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date May 2014
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

All subjects are required to meet the following inclusion criteria in order to be considered eligible for participation in this trial:

1. Subject is scheduled to undergo elective on-pump cardiac surgical procedure(s) for one or more of the following:

1. Mitral valve repair or replacement,

2. Aortic valve repair or replacement,

3. Tricuspid valve repair or replacement, or

4. Coronary Artery Bypass procedures;

2. Subject has history of a non-paroxysmal form of AF for greater than 3 months and has failed at least one attempt at electrical cardioversion or had a successful attempt at electrical cardioversion but had a recurrence of AF within 30 days of the cardioversion;

3. Age 18 to 80 years old;

4. Left ventricular ejection fraction (LVEF) = 30%;

5. Subject has no contraindications to intraoperative transesophageal echocardiography;

6. Subject has a life expectancy greater than 12 months; and

7. Willing and capable of providing Informed Consent to undergo surgery and participate in all examinations and follow-ups associated with this clinical trial.

A subject is considered to have failed electrical cardioversion if they did not achieve sinus rhythm for at least 30 seconds following the attempted cardioversion.

Exclusion Criteria:

Subjects will be excluded from participating in this trial if they meet any of the following exclusion criteria:

1. History of non-paroxysmal AF less than 3 months or for more than 5 years;

2. History of prior cardiac ablative surgical or catheter-based therapy;

3. Previous cardiac surgery (redo) or other intrapericardial procedures;

4. Class IV NYHA heart failure;

5. Known carotid artery stenosis greater than 80% or previous carotid endarterectomy;

6. Wolff-Parkinson-White syndrome;

7. Need for emergent cardiac surgery (e.g., cardiogenic shock);

8. Untreated hyperthyroidism;

9. Untreated hypothyroidism;

10. Acute pulmonary disease;

11. Electrolyte imbalance;

12. History of myocarditis;

13. Presence of a previously implanted device in or adjacent to the treatment target area that may alter the delivery of therapy (e.g., valvular prosthesis or ring, pacemaker with leads in coronary sinus or internal defibrillator leads);

14. History of pericarditis;

15. Previous left phrenic nerve paralysis;

16. Bullous lung disease;

17. Presence of active endocarditis, or local or systemic infection;

18. Recent myocardial infarction (< 3 months);

19. Renal failure requiring dialysis or hepatic failure or creatinine of >2 mg/dL preoperatively;

20. Antiarrhythmic drug therapy required for the treatment of a ventricular arrhythmia;

21. Preoperative need for an intra-aortic balloon pump or intravenous inotropes;

22. Severe peripheral arterial occlusive disease defined as claudication with minimal exertion;

23. Therapy resulting in compromised tissue integrity including: thoracic radiation, chemotherapy, long term treatment with oral or injected steroids, or known connective tissue disorders;

24. Documented left atrial size of 6 cm or more;

25. History of cerebrovascular disease or accident, including stroke or transient ischemic attack (TIA) within 6 months prior to enrollment;

26. Known contraindication to anticoagulant therapy or inability to comply with anticoagulant therapy;

27. Pregnancy, planned pregnancy (females of childbearing potential must have a negative pregnancy test prior to enrollment and agree not to become pregnant during the trial) or breastfeeding;

28. Forced expiratory volume in 1 second less than 30% of predicted value or need for home oxygen therapy; or

29. Surgical management of hypertrophic obstructive cardiomyopathy.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
The Estech COBRA® Surgical System
The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.

Locations

Country Name City State
United States Univ. of Michigan Cardiovascular Center Ann Arbor Michigan
United States Saint Joseph's Hospital of Atlanta Atlanta Georgia
United States Sisters of Charity, Providence Hospital Columbia South Carolina
United States North Shore Univ. Health System Evanston Illinois
United States Fairfax Hospital, Department of Cardiovascular and Thoracic Surgery Falls Church Virginia
United States Hartford Hospital Hartford Connecticut
United States The Univ. of Kansas Hospital Kansas City Kansas
United States Banner Good Samaritan Medical Center Mesa Arizona
United States Aurora St. Luke's Medical Center Milwaukee Wisconsin
United States Lenox Hill Hospital / North Shore-LIJ Health System New York New York
United States Advocate Christ Medical Center Oak Lawn Illinois
United States Mayo Clinic / St. Mary's Hospital Rochester Minnesota
United States Mohawk Valley Heart Institute / St. Elizabeth Medical Center Utica New York

Sponsors (1)

Lead Sponsor Collaborator
Endoscopic Technologies, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Efficacy Endpoint Proportion of subjects that achieve procedural and therapeutic success. Procedural success is defined as the performance of the protocol specified lesions with the designated devices. Therapeutic success is defined as freedom from AF, AFL (atrial flutter) and AT (atrial tachycardia, not including sinus tachycardia) following the blanking interval through Month 12. The primary efficacy endpoint will be assessed following the blanking interval through Month 12. No
Primary Primary Safety Endpoint A composite safety endpoint consisting of the proportion of subjects that experience one or more of the following early onset (i.e., within 30 days of the TCRF ablation procedure or hospital discharge, whichever is later) serious adverse events (SAEs):
Cardiac death;
Stroke and transient ischemic attack (TIA);
Myocardial infarction (MI);
Excessive bleeding; or
Atrioesophageal fistula.
The primary safety endpoint will be assessed within 30 days of the procedure or hospital discharge, whichever is later. Yes
Secondary Secondary Efficacy Endpoint The secondary efficacy endpoints include:
Proportion of subjects that achieve bilateral pulmonary vein conduction block.
AF burden at 6 and 12 months based on the proportion of time a subject is in AF (% of 24 hours) from the 24-hour continuous ECG monitor.
The secondary efficacy endpoints will be assessed following the procedure through the 12 month follow-up visit. No
Secondary Secondary Safety Endpoint The proportion of subjects with acute onset post-surgical symptomatic diaphragmatic paralysis that is still present at the Month 12 follow-up visit.
The proportion of subjects reporting one or more SAEs for each follow-up interval. The intervals will include the period from:
the surgical procedure for the surgical TCRF ablation through the Day 30 follow-up visit;
the Day 30 follow-up visit through the Month 3 follow-up visit;
the Month 3 follow-up visit through the Month 6 follow-up visit; and
the Month 6 follow-up visit through the Month 12 follow-up visit. Additionally, the proportion of subjects reporting one or more SAEs annually for years 2 and 3 post procedure.
The secondary safety endpoints will be assessed up to 3 years post procedure. Yes
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT03650556 - Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation N/A
Recruiting NCT04085731 - Driver-guided Ablation of Persistent Atrial Fibrillatiom
Withdrawn NCT02344394 - Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone vs Hybrid Ablation With PVI Plus Catheter Ablation N/A
Completed NCT01694563 - ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation N/A
Active, not recruiting NCT03643224 - DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation N/A
Withdrawn NCT05093868 - Electrographic Flow Mapping Validation in Patients With Persistent Atrial Fibrillation (EVAL AF) N/A
Completed NCT05152966 - Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II) N/A
Completed NCT05043883 - Automated Assessment of PVI Using a Novel EP Recording System N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific
Active, not recruiting NCT06124690 - Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas N/A
Completed NCT06260670 - FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation N/A
Not yet recruiting NCT05454111 - CARTO-Finder Guided Ablation Versus Multiscale Entropy Guided Ablation in Persistent Atrial Fibrillation N/A
Active, not recruiting NCT05077670 - Hybrid Characterization of Driver Sites During Atrial Fibrillation and Sinus Rhythm
Withdrawn NCT03835338 - WATCHMAN for Concomitant Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation Rhythm N/A
Completed NCT02275104 - Multimodal Image Processing Software to Guide Cardiac Ablation Therapy N/A
Not yet recruiting NCT05565183 - Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation. N/A
Completed NCT02274857 - Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures N/A
Completed NCT01014741 - Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation N/A